A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03).
Giuseppe ProcopioMélanie ClapsChiara PircherLuca PorcuPierangela SepeValentina GuadalupiUgo De GiorgiDavide BimbattiFranco NolèFrancesco CarrozzaSebastiano ButiRoberto IacovelliChiara CiccareseCristina MasiniCinzia BaldessariLaura DoniAntonio CusmaiAngela GernoneSarah ScagliariniSandro PignataFilippo de BraudElena VerzoniPublished in: Tumori (2022)
NCT03463681 - A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma (BREAKPOINT) - https://clinicaltrials.gov/ct2/show/NCT03463681.
Keyphrases
- renal cell carcinoma
- phase iii
- study protocol
- phase ii
- locally advanced
- clinical trial
- liver metastases
- computed tomography
- metastatic renal cell carcinoma
- randomized controlled trial
- squamous cell carcinoma
- open label
- cross sectional
- magnetic resonance imaging
- contrast enhanced
- rectal cancer
- positron emission tomography
- newly diagnosed
- pet ct